Strategic Analysis of the Opportunities for the Pharmaceutical and Biotechnology Industry in the 'New' EU Countries


USD 3,950.00

* Required Fields

USD 3,950.00


Be the first to review this product

This strategic analysis service looks into the market entry issues in the 'new' European Union (EU) countries. The service in powerpoint format (approximately 90 slides) focuses not just on the challenges for pharmaceutical and biotechnology companies wishing to enter the 'new' EU countries but also identifies opportunities within the 'new' EU for market growth. The research also looks into the strategies for achieving the maximum growth in the 'new' EU by the pharmaceutical and biotechnology companies.

Table of Contents

Strategic Analysis of the Opportunities for Pharmaceutical and Biotechnology Industry in the 'New' EU CountriesOverviewOverviewResearch Scope and MethodologyResearch Scope and MethodologyEuropean UnionEuropean UnionEuropean Union HealthcareEuropean Union Healthcare'New' EU Markets- The Facts'New' EU Markets- The FactsChallenges in the 'New' EU MarketChallenges in the 'New' EU MarketOpportunities in Clinical TrialsOpportunities in Clinical TrialsStrategic RecommendationsStrategic RecommendationsIndustry ParticipantsIndustry ParticipantsDecision Support DatabasesDecision Support DatabasesAbout Frost & SullivanOur TeamConsulting Capabilities

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.